Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Johnson and Johnson
McKinsey
Medtronic
Dow

Last Updated: December 4, 2021

DrugPatentWatch Database Preview

Patent: 9,879,088

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,879,088
Title:Disease therapy by inducing immune response to Trop-2 expressing cells
Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-.alpha.), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2.sup.+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.
Inventor(s): Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), Rossi; Edmund A. (Woodland Park, NJ), Rossi; Diane (Woodland Park, NJ)
Assignee: IBC Pharmaceuticals, Inc. (Morris Plains, NJ)
Application Number:15/497,931
Patent Claims:see list of patent claims

Details for Patent 9,879,088

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab For Injection 125514 2014-09-04 ⤷  Free Forever Trial 2032-08-14
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab Injection 125514 2015-01-15 ⤷  Free Forever Trial 2032-08-14
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 2014-12-22 ⤷  Free Forever Trial 2032-08-14
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 2017-10-04 ⤷  Free Forever Trial 2032-08-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Express Scripts
McKinsey
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.